Navigation Links
Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Date:8/8/2014

LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives. 

According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market.  In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.

"Promescent may seem like a miracle, but it is actually just great science," says Abraham.  "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation.  This means men are not deprived of sensation and neither are their partners."

Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:

http://www.kfiam640.com/media/podcast-john-and-ken-on-demand-JohnandKen/jane-wells-cnbc-6pm-86-25128155/

Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.

"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham.  "This helps men better satisfy their partners and gain sexual confidence."

Promescent is available on-line and over-the-counter at independent pharmacies across the nation.  It is safe, effective, and doctor recommended. 

For more information, please visit http://www.promescent.com/.

To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
5. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
6. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
7. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
8. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... In vitro diagnostics market firm Kalorama Information ... least ten diagnostic companies have successfully completed financings.  The ... a loan facility.  The size of these financings ranged ... Information provides a monthly IVD Market Trends Report ... "Diagnostics deals ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):